Biomarin Pharmaceutical Inc BMRN
0 trading plans running, 5 Form 144 notices for $4.3M
10-Q, 10-K and Form 144What BMRN's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Apr 13, 2023 to Nov 16, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary |
Adopted 10b5-1 plan | Mar 13, 2025 | 10-Q May 2, 2025 | ||
What the company wroteDuring the three months ended March 31, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities as set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Shares of Common Stock to be Sold (3) Expiration Date G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary Adoption March 13, 2025 X up to 28,107 November 3, 2025 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan. | |||||
| Erin Burkhart Group Vice President and Chief Accounting Officer |
Adopted 10b5-1 plan | Nov 26, 2024 | 10-K Feb 24, 2025 | ||
What the company wroteDuring the three months ended December 31, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Shares of Common Stock to be Sold (3) Expiration Date Erin Burkhart Group Vice President and Chief Accounting Officer Adoption November 26, 2024 X up to 6,246 May 30, 2025 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan. | |||||
| Brian R. Mueller Executive Vice President and Chief Financial Officer |
Adopted 10b5-1 plan | Sep 13, 2024 | 10-Q Oct 31, 2024 | ||
| Cristin M. Hubbard Executive Vice President and Chief Commercial Officer |
Adopted 10b5-1 plan | Sep 13, 2024 | 10-Q Oct 31, 2024 | ||
| V. Bryan Lawlis Director |
Adopted 10b5-1 plan | Feb 28, 2024 | 10-Q Apr 26, 2024 | ||
What the company wroteDuring the three months ended March 31, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Shares of Common Stock to be Sold (3) Expiration Date V. Bryan Lawlis Director Adoption February 28, 2024 X up to 6,600 August 30, 2024 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan. | |||||
| Erin Burkhart Group Vice President and Chief Accounting Officer |
Ended 10b5-1 plan | Nov 29, 2023 | 10-K Feb 26, 2024 | ||
What the company wroteDuring the three months ended December 31, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1 (1) Non- Rule 10b5-1 (2) Total Shares of Common Stock to be Sold (3) Expiration Date Erin Burkhart Group Vice President and Chief Accounting Officer Termination November 29, 2023 X up to 2,782 March 8, 2024 Erin Burkhart Group Vice President and Chief Accounting Officer Adoption November 29, 2023 X up to 5,709 November 29, 2024 (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. (2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. (3) Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan. | |||||
| G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary |
Adopted 10b5-1 plan | Sep 13, 2023 | 10-Q Nov 2, 2023 | ||
| Brian R. Mueller Executive Vice President and Chief Financial Officer |
Adopted 10b5-1 plan | Aug 23, 2023 | 10-Q Nov 2, 2023 | ||
| Henry J. Fuchs, M.D. President of Worldwide Research & Development |
Adopted 10b5-1 plan | Aug 17, 2023 | 10-Q Nov 2, 2023 | ||
| Jean-Jacques Bienaimé Chairman and Chief Executive Officer |
Adopted 10b5-1 plan | Aug 7, 2023 | 10-Q Nov 2, 2023 | ||
| Jeff Ajer Executive Vice President, Chief Commercial Officer |
Adopted 10b5-1 plan | Apr 13, 2023 | 10-Q Aug 2, 2023 | ||
What the company wroteDuring the three months ended June 30, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of BioMarin securities set forth in the table below. Type of Trading Arrangement Name Position Action Adoption/Termination Date Rule 10b5-1* Non- Rule 10b5-1** Total Shares of Common Stock to be Sold*** Expiration Date Jeff Ajer Executive Vice President, Chief Commercial Officer Adoption April 13, 2023 X up to 77,259 July 12, 2024 * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. *** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold will be dependent on the satisfaction of certain conditions as set forth in the written plan. | |||||
Show the other 3 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Apr 28, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Sep 2, 2026 | Davis George Eric Officer |
17,557 | $1.2M |
| May 7, 2026 | Friberg Gregory R Officer |
3,281 | $177K |
| Mar 11, 2026 | Guyer Charles Greg Officer |
16,486 | $997K |
| Feb 26, 2026 | Friberg Gregory R Officer |
6,326 | $382K |
| Feb 26, 2026 | Davis George Eric Officer |
26,061 | $1.6M |
From the Form 144 XML filed with the SEC, since Feb 26, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BMRN/export.csv") into a cell.